Jing Gong1, Hui Dong2, Qing-Song Xia2, Zhao-Yi Huang1, Ding-Kun Wang1, Yan Zhao1, Wen-Hua Liu3, Sheng-Hao Tu1, Ming-Min Zhang1, Qi Wang4, Fu-Er Lu5. 1. Department of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 2. Institute of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 3. Clinical Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 4. Institute of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. wangqixlp@163.com. 5. Institute of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. felu@tjh.tjmu.edu.cn.
Abstract
BACKGROUND: COVID-19 is highly contagious, and the crude mortality rate could reach 49% in critical patients. Inflammation concerns on disease progression. This study analyzed blood inflammation indicators among mild, severe and critical patients, helping to identify severe or critical patients early. METHODS: In this cross-sectional study, 100 patients were included and divided into mild, severe or critical groups according to disease condition. Correlation of peripheral blood inflammation-related indicators with disease criticality was analyzed. Cut-off values for critically ill patients were speculated through the ROC curve. RESULTS: Significantly, disease severity was associated with age (R = -0.564, P < 0.001), interleukin-2 receptor (IL2R) (R = -0.534, P < 0.001), interleukin-6 (IL-6) (R = -0.535, P < 0.001), interleukin-8 (IL-8) (R = -0.308, P < 0.001), interleukin-10 (IL-10) (R = -0.422, P < 0.001), tumor necrosis factor α (TNFα) (R = -0.322, P < 0.001), C-reactive protein (CRP) (R = -0.604, P < 0.001), ferroprotein (R = -0.508, P < 0.001), procalcitonin (R = -0.650, P < 0.001), white cell counts (WBC) (R = -0.54, P < 0.001), lymphocyte counts (LC) (R = 0.56, P < 0.001), neutrophil count (NC) (R = -0.585, P < 0.001) and eosinophil counts (EC) (R = 0.299, P < 0.001). With IL2R > 793.5 U/mL or CRP > 30.7 ng/mL, the progress of COVID-19 to critical stage should be closely observed and possibly prevented. CONCLUSIONS: Inflammation is closely related to severity of COVID-19, and IL-6 and TNFα might be promising therapeutic targets.
BACKGROUND:COVID-19 is highly contagious, and the crude mortality rate could reach 49% in critical patients. Inflammation concerns on disease progression. This study analyzed blood inflammation indicators among mild, severe and critical patients, helping to identify severe or critical patients early. METHODS: In this cross-sectional study, 100 patients were included and divided into mild, severe or critical groups according to disease condition. Correlation of peripheral blood inflammation-related indicators with disease criticality was analyzed. Cut-off values for critically illpatients were speculated through the ROC curve. RESULTS: Significantly, disease severity was associated with age (R = -0.564, P < 0.001), interleukin-2 receptor (IL2R) (R = -0.534, P < 0.001), interleukin-6 (IL-6) (R = -0.535, P < 0.001), interleukin-8 (IL-8) (R = -0.308, P < 0.001), interleukin-10 (IL-10) (R = -0.422, P < 0.001), tumor necrosis factor α (TNFα) (R = -0.322, P < 0.001), C-reactive protein (CRP) (R = -0.604, P < 0.001), ferroprotein (R = -0.508, P < 0.001), procalcitonin (R = -0.650, P < 0.001), white cell counts (WBC) (R = -0.54, P < 0.001), lymphocyte counts (LC) (R = 0.56, P < 0.001), neutrophil count (NC) (R = -0.585, P < 0.001) and eosinophil counts (EC) (R = 0.299, P < 0.001). With IL2R > 793.5 U/mL or CRP > 30.7 ng/mL, the progress of COVID-19 to critical stage should be closely observed and possibly prevented. CONCLUSIONS:Inflammation is closely related to severity of COVID-19, and IL-6 and TNFα might be promising therapeutic targets.
Authors: Mostafa M Khodeir; Hassan A Shabana; Abdullah S Alkhamiss; Zafar Rasheed; Mansour Alsoghair; Suliman A Alsagaby; Muhammad I Khan; Nelson Fernández; Waleed Al Abdulmonem Journal: J Infect Public Health Date: 2021-03-05 Impact factor: 7.537
Authors: Hui Shi; Yu Zuo; Srilakshmi Yalavarthi; Kelsey Gockman; Melanie Zuo; Jacqueline A Madison; Christopher Blair; Wrenn Woodward; Sean P Lezak; Njira L Lugogo; Robert J Woods; Christian Lood; Jason S Knight; Yogendra Kanthi Journal: J Leukoc Biol Date: 2020-09-01 Impact factor: 4.962
Authors: Antonio Julià; Irene Bonafonte-Pardàs; Antonio Gómez; María López-Lasanta; Mireia López-Corbeto; Sergio H Martínez-Mateu; Jordi Lladós; Iván Rodríguez-Nunez; Richard M Myers; Sara Marsal Journal: Sci Rep Date: 2021-06-01 Impact factor: 4.379
Authors: Amelia C Trombetta; Guilherme B Farias; André M C Gomes; Ana Godinho-Santos; Pedro Rosmaninho; Carolina M Conceição; Joel Laia; Diana F Santos; Afonso R M Almeida; Catarina Mota; Andreia Gomes; Marta Serrano; Marc Veldhoen; Ana E Sousa; Susana M Fernandes Journal: Front Immunol Date: 2021-06-23 Impact factor: 7.561